SEMAX is a synthetic peptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is an analogue of a fragment of the adrenocorticotropic hormone (ACTH) but is devoid of hormonal activity. It is primarily researched for its potent nootropic (cognitive-enhancing) and neuroprotective effects.

The primary mechanism of SEMAX is not fully elucidated but is known to be multifaceted. It is believed to modulate the brain’s dopaminergic and serotonergic systems. A key researched function is its ability to rapidly increase the expression of Brain-Derived Neurotrophic Factor (BDNF) and its receptor, TrkB, in the brain. BDNF is a crucial protein that supports the survival of existing neurons, encourages the growth and differentiation of new neurons (neurogenesis), and promotes synaptic plasticity, which is vital for learning and memory.

Due to its poor oral bioavailability, SEMAX is typically studied in an intranasal (nasal spray) form for research, which allows it to bypass the blood-brain barrier more effectively.

Research areas for SEMAX include:

• Cognitive Enhancement: Investigating its effects on improving attention, short-term memory, and learning capabilities, especially under conditions of fatigue or stress.

• Neuroprotection: Studying its ability to protect neural tissue from damage caused by hypoxia (oxygen deprivation), oxidative stress, and inflammation.

• Neurological Recovery: Researching its potential as a therapeutic agent in the recovery from ischemic stroke, traumatic brain injury (TBI), and other cerebrovascular incidents.

• Optic Nerve Disease: Examining its protective effects on the optic nerve and its potential use in treating conditions like optic neuritis and glaucoma.

CAS Number: 80714-61-0